Israeli biotech company begins trial for cancer immuno-oncology solution Nov 30 Written by Mukul Verma The company’s product, NTX1088, blocks the harmful overexpression of PVR proteins, which occurs in tumors caused by lung, breast, throat and other cancers. NectinCFF Mukul Verma Previous Previous Cancer Focus Fund Invests $5 Million to Support Human Trial of ISA's Immunotherapy to treat Uveal Melanoma Next Next Nectin Announces Extended Series A Financing to Over $25M and Start of Patient Dosing in Phase 1 Clinical Trial of First-in-Class Immunotherapy for Treatment of Patients with Advanced Solid Tumors
Israeli biotech company begins trial for cancer immuno-oncology solution Nov 30 Written by Mukul Verma The company’s product, NTX1088, blocks the harmful overexpression of PVR proteins, which occurs in tumors caused by lung, breast, throat and other cancers. NectinCFF Mukul Verma
